Rezdiffra (Resmetirom) Missed-Dose Protocol: What to Do If You Skip a Dose
Evidence-based missed-dose protocol for Rezdiffra (resmetirom), including timing rules, pharmacokinetic rationale, and clinical guidance for patients with MASH.
Resmetirom
5 source-based articles maintained by the HealthRX.com Editorial Team.
5articles
4topic areas covered
May 27, 2026latest review
Resmetirom library
Showing 5 of 5 clinical reviews.
Rezdiffra (Resmetirom) Pharmacokinetics (ADME): A Clinical Deep Dive
A guide to resmetirom absorption, distribution, metabolism, and excretion, covering liver-selective uptake, CYP2C8 pathways, drug interactions, and what MAESTRO-NASH data mean for dosing.
Rezdiffra (Resmetirom) Real-World Evidence: Registries, RWE, and Clinical Outcomes Beyond MAESTRO-NASH
A comprehensive review of resmetirom (Rezdiffra) real-world evidence from registries and post-marketing data, including mechanism of action, clinical effectiveness outside trial settings, and emerging safety signals.
Rezdiffra (Resmetirom) Regulatory Status: US, EU, Canada, UK Approval Tracker
Rezdiffra is not approved in Canada as of mid-2026: Madrigal filed a New Drug Submission with Health Canada, but no Notice of Compliance has been issued.
Rezdiffra Drug Interactions: Statins, Levothyroxine & More
Rezdiffra inhibits CYP2C8 and OATP1B1/1B3, raising levels of statins, pioglitazone and repaglinide; monitor thyroid drugs like levothyroxine and amiodarone closely.